Cold plasma therapy after artery treatment for diabetic foot ulcers with blocked leg arteries
Tests cold atmospheric plasma against sham treatment for diabetic foot ulcers with blocked leg arteries.
Key facts
- Who runs it
- Shenyang Medical College
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention for Diabetic Foot Ulcers With Lower Extremity Arterial Occlusion
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 9 Oct 2025
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cold Atmospheric Plasma (CAP)
- Sham CAP Therapy
- Infrapopliteal Endovascular Revascularisation
- Guideline-Based Standard DFU Care
- Record updated
- 22 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes and a foot ulcer that is not healing, with blocked arteries below the knee already opened by balloon angioplasty.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Type 1 or type 2 diabetes with HbA1c ≤10% (86 mmol/mol). At least one chronic foot ulcer lasting ≥3 weeks, Wagner-Armstrong grade 1D or 2D. Narrowed or blocked arteries below the knee, shown on ultrasound and/or CTA scan.
- Earlier treatment
- Must have had balloon angioplasty of the arteries below the knee, with the vessel successfully reopened (≤30% narrowing left). The ulcer must not have healed with standard care.
- Biomarker or test result
- HbA1c ≤10% (86 mmol/mol)
Main reasons for not taking part
- People on dialysis for end-stage kidney disease cannot join.
- Current use of negative pressure wound therapy, maggot therapy, wound antibiotics applied to the skin, or platelet-rich fibrin.
- Women who could become pregnant without effective birth control, or who are breastfeeding.
- Severe other illness with expected life of less than 6 months.
- Taking part in another clinical trial now or in the past 3 months.
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 1)Age between 18 and 80 years; diagnosed with type 1 or type 2 diabetes mellitus; with HbA1c ≤10%
- 2)Presence of at least one chronic foot ulcer persisting for ≥3 weeks, with no signs of healing despite guideline-directed standard care; ulcer classified as Wagner-Armstrong grade 1D or 2D
- 3)Imaging-confirmed infrapopliteal arterial stenosis or occlusion, assessed by vascular ultrasound and/or computed tomography angiography (CTA); all patients must have undergone infrapopliteal balloon angioplasty, with successful target vessel revascularisation confirmed intraoperatively (≤30% residual stenosis)
- 4)Signed written informed consent prior to study participation
Who cannot take part
- 1)Concurrent use of negative pressure wound therapy (NPWT) or maggot debridement therapy
- 2)Undergoing dialysis for end-stage renal disease
- 8)Any condition deemed unsuitable for trial participation at the discretion of the investigators
- 4)Use of platelet-rich fibrin (PRF) for wound treatment
- 3)Use of topical antibiotics with known biological activity on the wound
- 5)Women of childbearing potential without effective contraception, or currently breastfeeding
- 6)Presence of severe comorbidities involving other organ systems, with an estimated life expectancy of less than 6 months
- 7)Participation in another clinical trial within the past 3 months, or currently enrolled in another clinical study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate whether cold atmospheric plasma (CAP) combined with endovascular intervention can accelerate wound healing and improve safety outcomes in patients aged 18 to 80 years with diabetic foot ulcers (DFUs) complicated by lower extremity arterial occlusion.
Read full original descriptionShow less
The main questions it aims to answer are:
1. Does CAP treatment lead to a greater reduction in ulcer area by Week 4 compared to placebo?; 2. Is CAP therapy safe and well-tolerated in patients with DFUs after successful infrapopliteal revascularisation?;
Researchers will compare CAP treatment plus standard care to sham CAP (placebo) plus standard care to see if CAP improves wound healing more effectively and reduces adverse local symptoms.
Participants will:
1. Receive either active CAP therapy or sham CAP therapy once daily for 10 days following endovascular revascularisation 2. Undergo daily wound assessments for ulcer area, signs of infection, and pain scores 3. Complete quality-of-life questionnaires (EQ-5D and SF-12) at baseline and Week 4 4. Be followed through Week 4 to assess efficacy and safety endpoints
The 2 groups in the trial
- Cold Atmospheric Plasma (CAP) GroupTreatment being tested
Participants with diabetic foot ulcers (DFUs) and infrapopliteal arterial occlusion who receive CAP therapy once daily for 10 days following successful endovascular intervention.
Treatment: Cold Atmospheric Plasma (CAP), Infrapopliteal Endovascular Revascularisation, and Guideline-Based Standard DFU Care
- Sham CAP (Placebo) GroupPlacebo, for comparison
Participants with DFUs and infrapopliteal arterial occlusion who receive sham CAP therapy with an identical-looking device that does not produce active plasma.
Treatment: Sham CAP Therapy, Infrapopliteal Endovascular Revascularisation, and Guideline-Based Standard DFU Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention for Diabetic Foot Ulcers With Lower Extremity Arterial Occlusion: A Randomized, Double-Blind, Placebo-Controlled Trial
- Plain-language title
- Cold plasma therapy after artery treatment for diabetic foot ulcers with blocked leg arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07198061, who can take part
- Record updated
- 22 April 2026